Immunome, Inc. and Zentalis Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug Conjugate (ADC) with best-in-class potential on track for IND submission in first quarter of 2025, and Zentalis' proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zentalis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and the platform technology in addition to mid-to-high single-digit royalties.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.52 USD | +1.26% | +5.86% | +36.82% |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
May. 20 | Immunome Completes Purchase of Antibodies From Atreca | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
14.52 USD | +1.26% | +5.86% | 860M | ||
11.42 USD | +1.29% | -4.56% | 801M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.82% | 860M | |
+11.91% | 116B | |
+12.35% | 106B | |
-8.37% | 23.89B | |
-2.56% | 21.58B | |
-10.67% | 18.96B | |
-40.50% | 16.96B | |
-13.69% | 16.33B | |
+6.61% | 14.14B | |
+32.96% | 12.02B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate